10-Q · May 13, 2026
GRI Bio reported a net loss of $1.998 million for Q1 2026, significantly improved from a loss of $3.046 million in Q1 2025. The company's cash position remains stable at $11 million, while operating cash flow showed a…
Earnings analysis · 10-Q
GRI earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include revenue, margins, EPS, balance-sheet, cash-flow, or segment financial data, so quarterly operating trends cannot be assessed from this filing excerpt. Management implemented…
Read full summary
The supplied 10-Q text does not include revenue, margins, EPS, balance-sheet, cash-flow, or segment financial data, so quarterly operating trends cannot be assessed from this filing excerpt. Management implemented control changes during the quarter ended June 30, 2026, but disclosure controls remained ineffective because the previously identified material weakness had not yet operated long enough to be remediated. The most material new risk is Nasdaq's proposed $5 million MVLS requirement, under which the company's MVLS was already less than $5 million as of the filing date.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control Remediation Implemented
During the quarter ended June 30, 2026, management implemented multiple compensating controls and completed a redesign of the control environment, including enhanced monitoring, review procedures, and reassignment of responsibilities.
-
Additional Hiring No Longer Expected
Management stated that it does not currently expect to hire additional accounting personnel previously contemplated in the Annual Report, following the control redesign completed during the quarter ended June 30, 2026.
-
Nasdaq Requirement Currently Stayed
The company reported that the SEC stayed approval of Nasdaq's $5 million Market Value of Listed Securities requirement on July 29, 2026, so the requirement was not in effect as of the filing.
What to watch
-
Material Weakness Remains
Disclosure controls and procedures were ineffective as of June 30, 2026 because of a material weakness involving limitations in the accounting software, a limited number of accounting personnel, and insufficient segregation of duties over certain transactions.
-
Potential Nasdaq Suspension
As of the filing date, GRI Bio's Market Value of Listed Securities was less than $5 million. If Nasdaq's requirement becomes effective and MVLS remains below $5 million for 30 consecutive business days, trading could be immediately suspended and delisting proceedings initiated.
-
Limited Delisting Cure Protection
The Nasdaq MVLS requirement provides no cure or compliance period for suspension; although a Hearings Panel may grant an exception of up to 180 days, a hearing request would not automatically stay the suspension.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text. The filing states that cash runway and funding outlook were not discussed quantitatively.
Earlier filings 4
10-K · January 30, 2026
GRI Bio is a clinical-stage biopharmaceutical company focused on iNKT/dNKT-targeting oral therapies. Its Phase 2a trial of GRI-0621 in IPF (35 patients enrolled; 19 completed in treatment arm, 9 in placebo) met its…
10-Q · November 14, 2025
GRI Bio reported no revenue and a net loss of $3,359,000 for the quarter ended September 30, 2025 (net loss per share $(1.28)). Operating expenses increased materially year-over-year to $3,365,000 (up $1,235,000 vs.…
10-Q · August 14, 2025
GRI Bio reported a net loss of $(2,892) for Q2 2025 (three months ended June 30, 2025) and loss per share of $(1.31), in line with consensus. Operating expenses increased to $2,897 for the quarter from $2,257 in Q2 2024…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.